當(dāng)前位置：   首頁 > 需求大廳

 >  特色服務(wù) 

 >  信息服務(wù) 

1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開發(fā) 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

簡介：藥智人才是最專業(yè)的醫(yī)藥產(chǎn)業(yè)招聘平臺，與許多醫(yī)藥行業(yè)的知名企業(yè)都有合作，職位種類豐富，崗位更專業(yè)~ 賺取賞金規(guī)則（活動時間：5月13日-5月17日）： 1.免費(fèi)注冊/登錄藥智人才（https://job.yaozh.com/），上傳簡歷： 簡歷完善度≥80 可獲得50元賞金； 2.簡歷完成后，并截圖藥智人才簡歷板塊的完善度提交審核，并且備注藥智人才的用戶名/注冊手機(jī)信息； 3.審核通過后，賞金會在3個工作日內(nèi)審核并發(fā)放，如提交后有刪除簡歷的行為，視為作弊處理，對應(yīng)賞金將會被凍結(jié)不予提現(xiàn)。 4.特別福利：簡歷完善后既有機(jī)會直接內(nèi)推給名企噢~ 溫馨提示： 1.如果疑問可以聯(lián)系客服QQ：3413833812 2.一經(jīng)發(fā)現(xiàn)求職者在上傳簡歷期間有作弊等行為，藥智人才將取消其賞金并凍結(jié)該筆提現(xiàn)。 3.在法律允許的范圍內(nèi)，本活動一切解釋權(quán)歸藥智人才 下期活動預(yù)告 活動日期：5月20-5月24日 賞金金額：更多賺取賞金細(xì)則5月20日揭曉噢~   [更多]

1.論批生產(chǎn)記錄設(shè)計(jì)的有效性對產(chǎn)品質(zhì)量追溯的影響——以公司內(nèi)膠囊及片劑產(chǎn)品批生產(chǎn)記錄為例 2.Federal Health bulletin 4（1961）12:189 需要這個文獻(xiàn) 3.Morton RF, et al. Studies on the absorption, diffusion, and excretion of cycloserine. Antibiot Annu 1955-56; 3: 169-72. 4.Acta Gastroenterol Belg.1969,32（10）：771-777 A NEW ANTISPASMODIC DRUG IN THE TREATMENT OF BILIARY AND INTESTINAL DISCASCS:A CLINICAL TEST. 5.a process for preparing (S)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one https://priorart.ip.com/IPCOM/000238343   [更多]

藥物研發(fā)中心全套質(zhì)量管理體系文件，越詳細(xì)越好，價格可談！   [更多]

求歐洲藥典全套9.2英文版   [更多]

1、Drugs Fut 1989, 14(9): 875 ISSN 0377-8282 Copyright Clarivate Analytics CCC: 0377-8282 DOI: 10.1358/dof.1989.014.09.103408 2、Dionne, G. (BioChem Pharma Inc.); 1,3-Oxathiolane nucleoside analogues. EP 0526253; JP 1995500317; US 5538975; WO 9303027 . 3、Hoshi, A.; Casta?er, J.; Capecitabine. Drugs Fut 1996, 21, 4, 358 4、Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997, vol. 36, # 9, p. 816 - 818 5、DETERMINATION OF CLENBUTEROL HYDROCHLORIDE BY SEQUENTIAL INJECTION ANALYSIS COUPLED WITH CHEMILUMINESCENCE DETECTION 6、[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations]. 7、Agrati A. M., De Bartolo G., Palmieri G., Minerva Med., 83, 533-536(1992) 8、Dawes J., Hodson B. A., Pepper D. S., Thromb. Haemost, 62, 945-949(1989) 9、with mercury(II) diacetate,trifluoroacetic acid . Acta Chimica Hungarica 1986 vol.122 3-4 p261-272   [更多]

1.Arzneimittel Forschung/Drug research 1986 36(2)，p291-303. 2.The use of antithrombotic drugs in artery disease 3. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer ormation [J]. Diabetes, 2010, 59(Suppll): All(39-OR). 4.Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624. 5.Technology Reports of the Osaka University, , vol. 7, p. 177,182。   [更多]

根據(jù)已知省份、城市的醫(yī)院銷售數(shù)據(jù)樣本，根據(jù)樣本數(shù)據(jù)如何計(jì)算醫(yī)院銷售數(shù)據(jù)在全國的銷售量、銷售額？ 放大規(guī)則提供相關(guān)原理，思路，計(jì)算中所需要的樣本變量（字段，如：如“某藥品的藥品銷售額”與“樣本對于省份”，“樣本城市數(shù)量”、“樣本醫(yī)院數(shù)量”、“樣本醫(yī)院等級比例”等的關(guān)系），以及相關(guān)規(guī)格參數(shù)以及參數(shù)計(jì)算的方式，具體細(xì)節(jié)可私下溝通。   [更多]